Apollon Wealth Management
CMPX icon

Apollon Wealth Management’s Compass Therapeutics CMPX Stock Holding History

Apollon Wealth Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-19,687
Closed -$43.1K – 1667
2026
Q2 		$43.1K Buy
+19,687
New +$58.1K ﹤0.01% 1554
2025
Q4 		– Sell
-10,015
Closed -$35.1K – 1321
2025
Q3 		$35.1K Buy
+10,015
New +$31.6K ﹤0.01% 1307

Other funds holding CMPX

Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Simplicity Wealth
Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return
McAdam LLC
McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
SmartHarvest Portfolios
SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return
ACT Advisors
ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Apollon Wealth Management's CMPX Position: Q3 2026 in Review

Apollon Wealth Management sold out of Compass Therapeutics (CMPX) in Q3 2026, closing a stake of 19,687 shares — an estimated $43.1K sold.

Apollon Wealth Management first reported a position in CMPX in Q3 2025 and held it in 2 quarters. The position peaked at $43.1K in Q2 2026. 23 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Apollon Wealth Management reported no remaining Compass Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Apollon Wealth Management sold 19,687 Compass Therapeutics shares in Q3 2026, an estimated $43.1K.
  • Apollon Wealth Management first reported a position in Compass Therapeutics in Q3 2025 and held it in 2 quarters.
  • Apollon Wealth Management's Compass Therapeutics position peaked at $43.1K in Q2 2026.
  • 23 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Apollon Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.